Universal Access and Affordable Medicines

Our campaign promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.

About our work on access to medicines

Watch now

Publications

See all

Latest Developments

Transparency is a fundamental pillar for the success of the EU Vaccines Strategy

Dec 17, 2020

39 health and consumer organisations call for the public and their elected representatives to be given more scrutiny of EU COVID19 vaccine contracts

Putting medicines policy under the spotlight: EPHA’s #A2MDialogues

Nov 14, 2020

EPHA’s new series of online discussions, putting the spotlight on actionable solutions on access to medicines for decision-makers in Europe.

Recommendations for unleashing meaningful innovation through regulatory reform

Nov 10, 2020

A series of recommendations to generate better evidence on new medicines developed during the the first of the EPHA #A2MDialogues “Unleashing meaningful innovation through regulatory reform.”

See all

Analysis & Opinion

Best treatment for cancer patients in Europe?

Nov 14, 2020

If the EU wants to ensure “access to the best treatment for all” in its “Europe’s Beating Cancer plan” what changes need to be made to the assessment process for new cancer treatments?

The European Pharmaceutical Strategy: An inventory for action for Europe

Nov 14, 2020

What could we hope for from the upcoming EU Pharmaceutical Strategy, expected on 24 November

Getting it right: COVID19 vaccines procurement

Jun 30, 2020

How should the European Commission and Member States manage the process of finding vaccines to tackle COVID-19? EPHA sets out 9 recommendations the European Commission and national governments should full to protect the public interest.

See all